Trials
Search / Trial NCT06442267

Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support

Launched by MEDICAL UNIVERSITY OF VIENNA · Jun 2, 2024

Trial Information

Current as of February 08, 2025

Recruiting

Keywords

Ecmo Anticoagulation Thromboembolic Event Bleeding Extracorporeal Life Support Anticoagulant Heparin

ClinConnect Summary

This clinical trial is studying different blood-thinning medications used during a treatment called extracorporeal membrane oxygenation (ECMO), which helps patients with severe breathing or heart problems. Specifically, the trial compares three options: unfractionated heparin (the current standard), argatroban, and enoxaparin. The goal is to see if argatroban and enoxaparin are just as effective as heparin in preventing blood clots while patients are on ECMO.

To be eligible for this study, participants need to either require ECMO support or have started ECMO therapy within the last 12 hours. However, certain individuals are not eligible, such as those who are pregnant, have certain bleeding disorders, or have been on specific blood-thinning treatments before starting ECMO. If you choose to participate, you will be assigned randomly to receive one of the three medications, and researchers will monitor you to see how well the treatment works in preventing blood clots during your ECMO therapy. This study is currently recruiting participants and aims to help improve care for patients needing this critical support.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • either
  • require ECMO support or
  • have been started on ECMO therapy within the last 12 hours
  • Exclusion Criteria:
  • Patients exhibiting contraindications to anticoagulation in general or any of the three investigated substances
  • Patients who are pregnant
  • Patients suffering from a clinically relevant pre-existing coagulopathy
  • Patients, for whom screening, randomization and implementation of study protocol cannot be initiated within 12 hours after cannulation
  • Patients receiving ongoing therapeutic systemic anticoagulation prior to ECMO implantation, or exhibiting an indication for therapeutic anticoagulation (e.g., pulmonary embolism)
  • Patients whose total duration of ECMO support lasts less than 24 hours
  • Patients with start of ECMO support during CPR (eCPR)
  • Patients with passive decarboxylation, without an active pumping system
  • Patients, who have been weaned off ECMO support within the last 30 days
  • Patients with central ECMO cannulation and/or after cardiopulmonary bypass

Trial Officials

Johannes Gratz, PD, MD, PhD

Principal Investigator

Medical Univeristy of Vienna

About Medical University Of Vienna

The Medical University of Vienna is a leading research institution dedicated to advancing healthcare through innovative clinical research and education. Renowned for its commitment to excellence in medical science, the university fosters interdisciplinary collaboration among researchers, clinicians, and academic professionals. Its clinical trials encompass a wide range of medical disciplines, aiming to develop cutting-edge therapies and improve patient outcomes. With state-of-the-art facilities and a strong emphasis on ethical standards, the Medical University of Vienna is at the forefront of transforming scientific discoveries into practical applications that enhance global health.

Locations

Vienna, , Austria

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0